Plasma concentrations of buprenorphine 24 to 72 hours after dosing.
BACKGROUND
This study evaluated plasma buprenorphine concentrations 24-72 h following sublingual administration of a dose of buprenorphine solution, ranging from 16 mg/70 kg to 44 mg/70 kg, administered on a daily or thrice-weekly schedule. Additionally, this study evaluated the effects of different thrice-weekly buprenorphine dose schedules on opiate use and withdrawal symptoms.


METHODS
Opiate dependent subjects (n = 10) were maintained in an outpatient clinic for two 3-week periods at each of three thrice-weekly buprenorphine dose schedules (providing a weekly total buprenorphine dose of 64, 84 and 112 mg) and for 1 week of a daily buprenorphine dose of 16 mg/70 kg. Plasma samples were obtained 24, 48 and 72 h following administration of buprenorphine. Urine samples were also collected and opiate withdrawal symptoms, agonist effects and the use of heroin, cocaine, alcohol and other drugs, were assessed.


RESULTS
Plasma levels showed a wide range of intra- and inter-subject variability. Nonetheless, higher doses of buprenorphine resulted in higher plasma concentrations at each time point and plasma concentration decreased with time. There were no significant differences in heroin use across dosing. Rates of withdrawal symptoms were low and did not differ across dosing schedules.


CONCLUSIONS
In the two highest dose schedules, plasma levels 72 h following the administration of the highest dose and at 48 h after the lower dose, were comparable to plasma concentrations at 24 h following daily administration of 16 mg/70 kg of buprenorphine.
Department of Psychiatry, CMHC/SAC, Yale University School of Medicine, New Haven, CT 06519, USA.
M C
MC
Chawarski
R S
RS
Schottenfeld
P G
PG
O'Connor
J
J
Pakes
D000286:Administration, Sublingual; D002047:Buprenorphine / Q000097:blood* / Q000627:therapeutic use; D003042:Cocaine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D000431:Ethanol / Q000097:blood; D005260:Female; D003932:Heroin / Q000097:blood; D006801:Humans; D008297:Male; D009294:Narcotics / Q000097:blood* / Q000627:therapeutic use; D009293:Opioid-Related Disorders / Q000097:blood / Q000534:rehabilitation / Q000652:urine; D013375:Substance Withdrawal Syndrome / Q000097:blood / Q000175:diagnosis / Q000652:urine; D013997:Time Factors
D009294:Narcotics; D000431:Ethanol; D002047:Buprenorphine; D003932:Heroin; D003042:Cocaine